Tamaki et al. reported that administration of ARBs had inhibitory effects on HCC and prevented the development of HCC through inhibition of hypoxia-inducible factor-1α (HIF-1α) and the VEGF signaling pathway [31]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.